Clinical Trial

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-21.
Trial Details
NCT Number NCT07612189
Lead Sponsor NEOK Bio, Inc.
Conditions Locally Advanced (Unresectable) or Metastatic Solid Tumors
Enrollment 155 participants
Start Date 2026-04-22
Primary Completion 2029-02 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-06-01